ASAM National Practice Guideline Stakeholder Summit Held

by Brendan McEntee | October 9, 2015

More than ten medical societies, eight federal agencies and other patient and payer organizations met in late September to discuss strategies to help accelerate the adoption of ASAM’s newly released National Practice Guideline for the Use of Medications in the Treatment of Addiction Involving Opioid Use.

Read ASAM’s National Practice Guideline

ASAM developed the National Practice Guideline to provide recommendations on evidence-based treatment for opioid use disorder. For those wishing to learn more about the guideline, an upcoming webinar will summarize recommendations from the guideline and provide:

  • Fundamental components of an OUD patient assessment and diagnosis.
  • Recommendations for the prescribing of pharmacotherapy, including buprenorphine, methadone, naltrexone, and naloxone, for patients with addiction involving opioid use and overdose.
  • Recommendations that take into account the specific needs of special populations, including pregnant women, individuals with pain, adolescents, patients with co-occurring psychiatric disorders and in the criminal justice system.

The first webinar will be on Wednesday October, 28 at 3:00 PM Eastern. A full listing of upcoming webinars, as well as additional guideline material including a mobile application and a medication bioequivalence calculator are available online at:

A re-broadcast of the September 24th special announcement event at the National Press Club in Washington D.C. is available below.

Leave a comment